Nicorandil-d4
(Synonyms: 尼可地尔 d4) 目录号 : GC49086
An internal standard for the quantification of nicorandil
Cas No.:1132681-23-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nicorandil-d4 is intended for use as an internal standard for the quantification of nicorandil by GC- or LC-MS. Nicorandil is an activator of sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel Kir6.2 (EC50 = ~10 µM) and a nitric oxide (NO) donor.1,2 It is selective for SUR2B/Kir6.2 over the SUR2A/Kir6.2 channel (EC50 = >500 µM).1 Nicorandil activates soluble guanylate cyclase in a cell-free assay and relaxes partially depolarized isolated bovine coronary artery strips (EC50 = 4.4 µM).3 It decreases mean blood pressure, coronary resistance, and heart rate, as well as increases coronary sinus outflow, in dogs when administered intravenously at a dose of 1 mg/kg.4 Nicorandil increases survival and decreases infarct size in a rabbit model of myocardial ischemia-reperfusion injury induced by left coronary artery occlusion.5 Formulations containing nicorandil have been used in the treatment of angina pectoris.
1.Shindo, T., Yamada, M., Isomoto, S., et al.SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandilBr. J. Pharmacol.124(5)985-991(1998) 2.Frampton, J., Buckley, M.M., and Fitton, A.Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectorisDrugs44(4)625-655(1992) 3.Holzmann, S.Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75)J. Cardiovasc. Pharmacol.5(3)364-370(1983) 4.Taira, N., Satoh, K., Yanagisawa, T., et al.Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75)Clin. Exp. Pharmacol. Physiol.6(3)301-316(1979) 5.Das, B.C., Sarkar, C., and Karanth, S.K.Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/reperfusion-induced arrhythmias and infarct size in anesthetized rabbitsNaunyn-Schmiedeberg’s Arch. Pharmacol.364(5)383-396(2001)
| Cas No. | 1132681-23-2 | SDF | |
| 别名 | 尼可地尔 d4 | ||
| Canonical SMILES | O=C(C1=C([2H])N=C([2H])C([2H])=C1[2H])NCCO[N+]([O-])=O | ||
| 分子式 | C8H5D4N3O4 | 分子量 | 215.2 |
| 溶解度 | DMSO: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6468 mL | 23.2342 mL | 46.4684 mL |
| 5 mM | 0.9294 mL | 4.6468 mL | 9.2937 mL |
| 10 mM | 0.4647 mL | 2.3234 mL | 4.6468 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。